Device-lead abnormalities and function after transcatheter tricuspid valve replacement
Europace · 07.10.2025 · 27 (10)
DOI: 10.1093/europace/euaf219 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Europace, online erschienen am 16.10.2025. Verfasst von Muhannad Abbasi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic Rochester, 200 1st ST SW, Rochester, MN 55902, USA. Hauptthemen laut MEDLINE: Tricuspid Valve Insufficiency, Pacemaker, Artificial, Heart Valve Prosthesis Implantation, Defibrillators, Implantable. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
The increasing adoption of transcatheter tricuspid valve replacement (TTVR) offers a promising therapeutic option for patients with severe tricuspid regurgitation. However, many of these patients have pre-existing cardiac implantable electronic devices (CIEDs), raising concerns about potential lead-related complications. Despite these concerns, limited data exist on the impact of TTVR on CIED integrity and function. This study aimed to evaluate the impact of TTVR on CIED lead function, including pacing thresholds, sensing, and impedance, in patients undergoing TTVR with the EVOQUE valve system. Methods and results A retrospective observational study was conducted at Mayo Clinic Rochester, including 32 consecutive patients who underwent TTVR with pre-existing CIEDs. A total of 32 patients were included, with a mean age of 79.2 ± 8.4 years; 59% were female. A total of 62.5% had a permanent pacemaker, 12.5% had an implantable cardioverter-defibrillator, 15.6% had a cardiac resynchronization therapy pacemaker, and 9.4% had a cardiac resynchronization therapy defibrillator. Following TTVR, 10 (31%) of patients developed lead function changes during a median device follow-up of 210 days (IQR: 43–307 days). The right ventricular lead was primarily affected, with only one case involving an atrial lead. Neither the Ottawa score nor the anatomical lead position reliably predicted lead abnormality (P = 0.86 and P = 0.53, respectively). R-wave sensing changes were the most common lead change observed, affecting 55% of cases. In 67% of these cases, R-wave sensing alterations occurred as an isolated finding, with no significant change in impedance or thresholds, and were managed conservatively without any need for device reprogramming. Four patients (13%) had findings concerning for a lead insulation breach, in which one (3%) required a lead revision. Among five patients with follow-up exceeding 600 days, two patients exhibited a statistically significant gradual decline in impedance without other lead dysfunction, suggesting potential subclinical lead degradation.
Conclusion
Transcatheter tricuspid valve replacement with the EVOQUE system in the setting of cardiac device leads is associated with lead function changes in 31%. The majority of lead-related changes were managed conservatively, but 13% of patients had findings concerning for an insulation breach. Future studies should focus on refining implantation techniques and defining optimal strategies for managing device-lead interactions in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Mayo Clinic Rochester, 200 1st ST SW, Rochester, MN 55902, USA.
- Department of Cardiovascular Medicine, Mayo Clinic Florida, Jacksonville, FL, USA.
- Department of Cardiovascular Surgery, Mayo Clinic Rochester, Rochester, MN, USA.
ORCID-Profile: Ammar M Killu, Christoff Van Niekerk, Abhishek Deshmukh, Malini Madhavan, Yong-Mei Cha, Siva K Mulpuru, Paul A Friedman, Kimberly Holst, Mackram F Eleid, Alan Sugrue
Zitieren
APA
Abbasi, M., Killu, A. M., Van Niekerk, C., Deshmukh, A., Madhavan, M., Cha, Y. M., Mulpuru, S. K., Friedman, P. A., Holst, K., Rihal, C. S., Eleid, M. F., & Sugrue, A. (2025). Device-lead abnormalities and function after transcatheter tricuspid valve replacement. Europace, 27(10). https://doi.org/10.1093/europace/euaf219
Vancouver
Abbasi M, Killu AM, Van Niekerk C, Deshmukh A, Madhavan M, Cha YM, et al. Device-lead abnormalities and function after transcatheter tricuspid valve replacement. Europace. 2025;27(10). doi:10.1093/europace/euaf219
BibTeX
@article{Abbasi2025,
author = {Abbasi, Muhannad and Killu, Ammar M and Van Niekerk, Christoff and Deshmukh, Abhishek and Madhavan, Malini and Cha, Yong-Mei and Mulpuru, Siva K and Friedman, Paul A and Holst, Kimberly and Rihal, Charanjit S and Eleid, Mackram F and Sugrue, Alan},
title = {Device-lead abnormalities and function after transcatheter tricuspid valve replacement},
journal = {Europace},
year = {2025},
volume = {27},
number = {10},
doi = {10.1093/europace/euaf219}
}
EUVIMED